An Overview of venous thromboembolism (VTE) in patients with haematological malignancy

Md. Manirul Islam (1) , Dr. Gazi Yeasinul Islam (2)
(1) , Bangladesh
(2) , Bangladesh

Full text article

Generated from XML file


Castelli R, Ferrari B, Cortelezzi A, Guariglia A. Thromboembolic complications in malignant haematological disorders. Curr Vasc Pharmacol 2010;8:482–94.

De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost. 2005;3:1985-92.

Goyal G & Bhatt V. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia. Future oncology. 11. 1-12. 10.2217

Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia 27(3), 553–559 (2013).

Grace RF, Dahlberg SE, Neuberg D et al. The frequency and management of asparaginase related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br. J. Haematol. 152(4), 452–459 (2011)

Abbott LS, Deevska M, Fernandez CV et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 114(25), 5146–5151 (2009).

Vu K, Luong NV, Hubbard J, Zalpour A, Faderl S, Thomas DA, et al. A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center. Cancer Med. 2015;4:27-35.

Libourel EJ, Klerk CPW, van Norden Y, de Maat MPM, Kruip MJ, Sonneveld P, et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood. 2016;128:1854-61.

Taylor FB, Jr., Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-30.

Runde V,Aul C,Heyll A,Schneider W. All-trans retinoic acid? Not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia. Blood 1992; 79: 534– 535.

Hashimoto S,Koike T,Tatewaki W, et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 1994; 8: 1113– 1115.

Choudhry A & Deloughery. Bleeding and thrombosis in acute promyelocytic leukemia. American journal of hematology. 2012. 87. 596-603.

Falanga A, Rickles FR. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program 2007; 165– 171.

Whittle AM, Allsup DJ, Bailey JR. Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism. Leuk Res. 2011;35:419-21.

Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogne JM. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis. JAMA Oncol. 2016.

Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia 2012;26:563–71.

Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica 2010;9:1788–91.

Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114–24.

Barbui T, Finazzi G, Falanga A. Mueloproliferative neoplasms and thrombosis. Blood 2013;122:2176–84.

Barbui T. How to manage thrombosis in myeloproliferative neoplasms. Curr Opin Oncol 2011;23:654–8.

Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–53.

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-7.

Lund JL, Ostgard LS, Prandoni P, Sorensen HT, de Nully Brown P. Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark. Thromb Res. 2015;136:917-23.

Lekovic D, Miljic P, Mihaljevic B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Thromb Res. 2010;126:477-80.

Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974

Richardson P, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M, et al. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol. 2011;153:212- 21

Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al.; International Myeloma Working Group. Prevention of thalidomide and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414–23.

Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33:654-6.

Mantha S, Miao Y, Wills J, Parameswaran R, Soff GA. Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. J Thromb Thrombolysis. 2017;43:514-8.


Md. Manirul Islam (Primary Contact)
Dr. Gazi Yeasinul Islam
Author Biographies

Md. Manirul Islam

Assistant Professor of Haematology, Dhaka Medical College

Dr. Gazi Yeasinul Islam

Dhaka Medical College Hospital

Islam MM, Islam GY. An Overview of venous thromboembolism (VTE) in patients with haematological malignancy. Haematol J Bangladesh [Internet]. 2024 Feb. 14 [cited 2024 Mar. 4];7(1):52-8. Available from:

Article Details

How to Cite

Islam MM, Islam GY. An Overview of venous thromboembolism (VTE) in patients with haematological malignancy. Haematol J Bangladesh [Internet]. 2024 Feb. 14 [cited 2024 Mar. 4];7(1):52-8. Available from: